Oxford Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Oxford Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,395	Closed	-$365K	–	1730
2019 Q3	$365K	Buy	18,395 +7,239	+65%	+$151K	0.01%	1388
2019 Q2	$236K	Buy	+11,156	New	+$233K	0.01%	1509
2017 Q1	–	Sell	-91,795	Closed	-$1.69M	–	1389
2016 Q4	$1.69M	Buy	91,795 +74,706	+437%	+$1.45M	0.06%	370
2016 Q3	$324K	Buy	+17,089	New	+$310K	0.01%	662

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oxford Asset Management's AMPH Position: Q4 2019 in Review

Oxford Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2019, closing a stake of 18,395 shares — an estimated $365K sold.

Oxford Asset Management first reported a position in AMPH in Q3 2016 and held it in 4 quarters. The position peaked at $1.69M in Q4 2016. 119 funds tracked by Wall St. Rank hold AMPH as of Q4 2019.

Oxford Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 18,395 Amphastar Pharmaceuticals shares in Q4 2019, an estimated $365K.
Oxford Asset Management first reported a position in Amphastar Pharmaceuticals in Q3 2016 and held it in 4 quarters.
Oxford Asset Management's Amphastar Pharmaceuticals position peaked at $1.69M in Q4 2016.
119 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.